Compare Novartis AG (NVS) vs First Trust Cloud Computing ETF (SKYY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs First Trust Cloud Computing ETF — how do they compare? Novartis AG trades at $143.11 (market cap $268.57B), while First Trust Cloud Computing ETF trades at $170.83 (market cap $3.47B). The key difference: Novartis AG is far larger — about 77.4× First Trust Cloud Computing ETF's market cap, and Novartis AG pays a 3.31% dividend while First Trust Cloud Computing ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and First Trust Cloud Computing ETF for 84 Days on average.
| NVS | SKYY | |
|---|---|---|
Market Cap | $268.57B | $3.47B |
Volume | 1,532,573 | 176,159 |
Sector | Health | — |
52-Week High | $168.62 | $171.01 |
52-Week Low | $121.80 | $104.16 |
Typical Hold Time | 82 Days | 84 Days |
Enterprise Value | $309.89B | — |
Dividend Yield | 3.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.28, up 1.77% on the day, with a neutral technical signal and mixed earnings history. The company reported strong 2025 revenue of $56.67B and a net income margin of 22.5%, supported by a recent $7.8B licensing deal with China's Abogen. However, recent clinical trial setbacks and an ongoing law firm investigation introduce uncertainty.
The outlook is balanced; solid profitability and a consensus price target of $146.00 suggest modest upside, but risks from pipeline failures and heightened M&A scrutiny warrant caution. Investor sentiment is mixed, with analysts predominantly holding a neutral stance amid evolving business developments.
SKYY, the First Trust Cloud Computing ETF, trades at $170.78, down 0.13% on the day but near its 52-week high. Technical indicators show a bullish trend with strong moving average support, while oscillators are neutral. The fund provides diversified exposure to the cloud computing sector, benefiting from AI adoption and digital transformation trends. Recent news highlights a new 52-week high and institutional activity, reflecting positive momentum.
The outlook for SKYY is favorable, driven by secular growth in cloud infrastructure and AI demand. Key opportunities include exposure to hyperscaler capex and data center investments without heavy concentration in mega-cap tech. Risks involve sector volatility, competitive pressures, and macroeconomic sensitivity. Analyst sentiment is constructive, with the ETF positioned to capitalize on long-term technology shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About First Trust Cloud Computing ETF
The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index is designed to track the performance of companies involved in the cloud computing industry.
Read more on SKYY →
